Brokerages expect Immune Design Corp (NASDAQ:IMDZ) to announce ($0.39) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Immune Design’s earnings, with estimates ranging from ($0.46) to ($0.32). Immune Design posted earnings of ($0.57) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 31.6%. The firm is scheduled to issue its next quarterly earnings results on Tuesday, March 6th.

On average, analysts expect that Immune Design will report full-year earnings of ($1.89) per share for the current fiscal year, with EPS estimates ranging from ($2.00) to ($1.76). For the next year, analysts expect that the firm will post earnings of ($1.40) per share, with EPS estimates ranging from ($1.58) to ($1.24). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Immune Design.

Immune Design (NASDAQ:IMDZ) last issued its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.63) by $0.11. Immune Design had a negative return on equity of 68.69% and a negative net margin of 619.62%. The business had revenue of $0.52 million during the quarter, compared to analysts’ expectations of $0.62 million.

Several equities analysts recently weighed in on the company. ValuEngine lowered Immune Design from a “hold” rating to a “sell” rating in a research note on Monday, October 2nd. Cowen restated a “buy” rating on shares of Immune Design in a research note on Monday, December 11th. Royal Bank of Canada assumed coverage on Immune Design in a research note on Thursday, September 14th. They issued an “outperform” rating and a $20.00 price target for the company. Zacks Investment Research upgraded Immune Design from a “hold” rating to a “buy” rating and set a $4.75 price target for the company in a research note on Monday, November 6th. Finally, Wells Fargo & Company lowered Immune Design from an “outperform” rating to a “market perform” rating and cut their price target for the company from $29.00 to $10.00 in a research note on Tuesday, October 17th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $13.19.

Immune Design (IMDZ) opened at $3.60 on Monday. Immune Design has a 52 week low of $3.50 and a 52 week high of $13.05.

In other news, Director Peter Svennilson acquired 2,681,000 shares of the business’s stock in a transaction on Friday, October 27th. The stock was bought at an average cost of $4.10 per share, for a total transaction of $10,992,100.00. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Leo Guthart acquired 2,439,000 shares of the business’s stock in a transaction on Friday, October 27th. The shares were purchased at an average price of $4.10 per share, with a total value of $9,999,900.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 5,290,000 shares of company stock valued at $21,777,900. 20.70% of the stock is owned by company insiders.

A number of large investors have recently bought and sold shares of IMDZ. Bank of America Corp DE increased its stake in Immune Design by 123.3% during the 1st quarter. Bank of America Corp DE now owns 15,246 shares of the biotechnology company’s stock worth $104,000 after buying an additional 8,418 shares in the last quarter. State of Wisconsin Investment Board purchased a new stake in Immune Design during the 2nd quarter worth approximately $117,000. Alliancebernstein L.P. purchased a new stake in Immune Design during the 2nd quarter worth approximately $118,000. Virtu KCG Holdings LLC purchased a new stake in shares of Immune Design in the second quarter valued at approximately $153,000. Finally, Dimensional Fund Advisors LP grew its position in shares of Immune Design by 9.3% in the second quarter. Dimensional Fund Advisors LP now owns 18,896 shares of the biotechnology company’s stock valued at $184,000 after purchasing an additional 1,600 shares in the last quarter. Institutional investors own 29.38% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/18/0-39-earnings-per-share-expected-for-immune-design-corp-imdz-this-quarter.html.

Immune Design Company Profile

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Get a free copy of the Zacks research report on Immune Design (IMDZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Immune Design (NASDAQ:IMDZ)

Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.